Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort

被引:268
作者
Lawn, SD
Badri, M
Wood, R
机构
[1] Univ Cape Town, Fac Hlth Sci, Desmond Tutu HIV Ctr, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa
[2] London Sch Hyg & Trop Med, Clin Res Unit, Dept Infect & Trop Med, London WC1, England
基金
英国惠康基金;
关键词
antiretroviral treatment; HAART; tuberculosis; HIV; Africa;
D O I
10.1097/01.aids.0000194808.20035.c1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To determine the long-term incidence of tuberculosis (TB) and associated risk factors among individuals receiving HAART in South Africa. Design: Prospective cohort study. Methods: Microbiologically or histologically confirmed incident TB was identified in a hospital-based cohort of 346 patients receiving HAART between 1996 and 2005 in Cape Town. Results: The TB incidence density rate was 3.5/100 person-years in the first year and significantly decreased during follow-up, reaching 1.01/100 person-years in the fifth year (P = 0.002 for trend). TB incidence during the study was highest among patients with baseline CD4 cell counts < 100 cells/mu l and those with World Health Organization (WHO) clinical stage 3 or 4 disease (5.71 and 3.88/100 person-years, respectively). Risk of TB was independently associated with CD4 cell count < 100 cells/mu l (adjusted risk ratio [ARR], 2.38; 95% confidence interval (CI), 1.01 -5.60; P = 0.04), WHO stage 3 or 4 disease (ARR, 3.60; 95% Cl, 1.32-9.80; P = 0.01) and age < 33 years (ARR, 2.86; 95% Cl, 1.29-6.34; P = 0.01). Risk of TB was not independently associated with plasma viral load, previous history of TB, low socioeconomic status or sex. Despite similar virological responses to HAART, blood CD4 cell count increases were much smaller among patients who developed TB than among those who remained free of TB. Conclusions: Incidence of TB continues to decrease during the first 5 years of HAART and so HAART may contribute more to TB control in low-income countries than was previously estimated from short-term follow-up. Patients with advanced pretreatment immunodeficiency had persistently increased risk of TB during HAART; this may reflect limited capacity for immune restoration among such patients. (c) 2005 Lippincott Williams & Wilkins.
引用
收藏
页码:2109 / 2116
页数:8
相关论文
共 34 条
[1]   Positive effects of combined antiretroviral therapy on CD4(+) T cell homeostasis and function in advanced HIV disease [J].
Autran, B ;
Carcelain, G ;
Li, TS ;
Blanc, C ;
Mathez, D ;
Tubiana, R ;
Katlama, C ;
Debre, P ;
Leibowitch, J .
SCIENCE, 1997, 277 (5322) :112-116
[2]   Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines [J].
Badri, M ;
Bekker, LG ;
Orrell, C ;
Pitt, J ;
Cilliers, F ;
Wood, R .
AIDS, 2004, 18 (08) :1159-1168
[3]   Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study [J].
Badri, M ;
Wilson, D ;
Wood, R .
LANCET, 2002, 359 (9323) :2059-2064
[4]   Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy [J].
Brodt, HR ;
Kamps, BS ;
Gute, P ;
Knupp, B ;
Staszewski, S ;
Helm, EB .
AIDS, 1997, 11 (14) :1731-1738
[5]   Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy [J].
Carcelain, G ;
Debré, P ;
Autran, B .
CURRENT OPINION IN IMMUNOLOGY, 2001, 13 (04) :483-488
[6]   Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count -: A randomized, double-blind, placebo-controlled trial [J].
Currier, JS ;
Williams, PL ;
Koletar, SL ;
Cohn, SE ;
Murphy, RL ;
Heald, AE ;
Hafner, R ;
Bassily, EL ;
Lederman, HM ;
Knirsch, C ;
Benson, CA ;
Valdez, H ;
Aberg, JA ;
McCutchan, JA .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (07) :493-503
[7]  
De Cock KM, 1999, INT J TUBERC LUNG D, V3, P457
[8]   Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy [J].
Dean, GL ;
Edwards, SG ;
Ives, NJ ;
Matthews, G ;
Fox, EF ;
Navaratne, L ;
Fisher, M ;
Taylor, GP ;
Miller, R ;
Taylor, CB ;
de Ruiter, A ;
Pozniak, AL .
AIDS, 2002, 16 (01) :75-83
[9]   Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy:: a collaborative analysis of prospective studies [J].
Egger, M ;
May, M ;
Chêne, G ;
Phillips, AN ;
Ledergerber, B ;
Dabis, F ;
Costagliola, D ;
Monforte, AD ;
de Wolf, F ;
Reiss, P ;
Lundgren, JD ;
Justice, AC ;
Staszewski, S ;
Leport, C ;
Hogg, RS ;
Sabin, CA ;
Gill, MJ ;
Salzberger, B ;
Sterne, JAC .
LANCET, 2002, 360 (9327) :119-129
[10]   Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy [J].
Girardi, E ;
Antonucci, G ;
Vanacore, P ;
Palmieri, F ;
Matteelli, A ;
Iemoli, E ;
Carradori, S ;
Salassa, B ;
Pasticci, MB ;
Raviglione, MC ;
Ippolito, G .
EUROPEAN RESPIRATORY JOURNAL, 2004, 24 (01) :11-17